TITLE

Medroxyprogesterone acetate, a progestin and partial glucocorticoid agonist/antagonist with anti-inflammatory activity in IBD, does not suppress the level of circulating lymphocytes

AUTHOR(S)
Schreiber, Alan D; Indik, Zena K; Rose, Martin
PUB. DATE
September 2003
SOURCE
American Journal of Gastroenterology;Sep2003 Supplement, Vol. 98, pS249
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
An abstract of the article concerning the non-suppression of the level of circulating lymphocytes in medroxyprogesterone acetate is presented.
ACCESSION #
66954762

 

Related Articles

  • Histological changes induced by medroxyprogesterone acetate on the uterus of ovariectomized rabbits. Rosas-Velasco, César; Pérez-Martínez, Mario; Castillo-Juárez, Héctor; Flores-Pérez, Fernando Iván // Veterinaria México;abr-jun2007, Vol. 38 Issue 2, p207 

    The objective of this study was to evaluate the effect of medroxyprogesterone acetate (MPA) on the number and tissular distribution of CD14+ macrophages and BB-2 lymphocytes. A total of 15 white New Zealand rabbits were ovariectomized and, 3 weeks after surgery, 5 groups were formed and all...

  • Just say no todepo.  // Herizons;Fall97, Vol. 11 Issue 4, p13 

    Cites a study showing the percentage of women who used Depo Provera in 1996.

  • Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the pro-proliferative signal of CD40-ligand, in part through increased 15dΔ12,14,PGJ2. Hayden, R. E.; Pratt, G.; Davies, N. J.; Khanim, F. L.; Birtwistle, J.; Delgado, J.; Pearce, C.; Sant, T.; Drayson, M. T.; Bunce, C. M. // Leukemia (08876924);Feb2009, Vol. 23 Issue 2, p292 

    B-cell chronic lymphocytic leukemia (CLL), the most common leukemia in older adults, remains largely incurable and novel treatments are urgently required. We previously reported powerful pro-apoptotic actions of bezafibrate (BEZ) and medroxyprogesterone acetate (MPA) against Burkitts lymphoma...

  • Recovery of bone density in women who stop using medroxyprogesterone acetate. Cundy, T.; Cornish, J.; Evans, M.C.; Roberts, H.; Reid, I.R. // BMJ: British Medical Journal (International Edition);1/22/94, Vol. 308 Issue 6923, p247 

    Examines the recovery of bone density in women who stop using medroxyprogesterone acetate. Investigation of the reversibility of bone loss; Mean increase in bone density in the lumbar spine; Factors influencing the degree of recovery.

  • Drug Regulation in the United States and the United Kingdom: The Depo-Provera Story. Richard, Barbara W.; Lasagna, Louis // Annals of Internal Medicine;Jun87, Vol. 106 Issue 6, p886 

    Discusses the drug regulation in the United States and Great Britain on the injectable contraceptive agent depot medroxyprogesterone acetate (DMPA). Controversy on the marketing of the contraceptive; Regulatory of Depo-Provera developed by Upjohn Co.; Comparison of regulatory processes between...

  • medroxyprogesterone acetate.  // Taber's Cyclopedic Medical Dictionary (2009);2009, Issue 21, p1427 

    A definition of the term "medroxyprogesterone acetate" is presented, which refers to a progestational agent used to treat secondary amenorrhea, abnormal uterine bleeding, and advanced endometrial and renal malignancies.

  • New guidance underscores DMPA's safety, efficacy in long-term use.  // Contraceptive Technology Update;Nov2008, Vol. 29 Issue 11, p121 

    The article discusses a committee opinion released by the American College of Obstetricians and Gynecologists which stated that concerns about the effects of the contraceptive injection depot medroxyprogesterone acetate on bone mineral density (BMD) should not prevent clinicians from prescribing...

  • Paying the price for birth control: Depo Provera in the north. Sarkadi, Laurie // Herizons;Spring95, Vol. 9 Issue 1, p23 

    Discusses the use of Depo-Provera as contraceptive in the Northwest Territories. Concern over the long-term health effects of the injected contraceptive; Health and Welfare Canada's policy against the marketing or promotion of the hormone injections; Efforts to ensure that women who are...

  • THE IMPACT OF DEPO-PROVERA ON BONE MINERAL DENSITY IN RELATION TO AGE AT FIRST DOSE AND DURATION OF USE.  // Osteoporosis International;Nov2004 Supplement 2, Vol. 15, pS5 

    The article presents an abstract "The Impact of Depo-Provera on Bone Mineral Density in Relation to Age at First Dose and Duration of Use," by P. Albertazzi, M. Botazzi and S. A. Steel.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics